

# Beta3 Adrenoceptors Substitute the Role of M<sub>2</sub> Muscarinic Receptor in Coping with Cold Stress in the Heart: Evidence from M<sub>2</sub>KO Mice

Jan Benes · Martina Novakova · Jana Rotkova ·  
Vladimir Farar · Richard Kvetnansky ·  
Vladimir Riljak · Jaromir Myslivecek

Received: 21 September 2011 / Accepted: 3 December 2011 / Published online: 6 January 2012  
© Springer Science+Business Media, LLC 2011

**Abstract** We investigated the role of beta3-adrenoceptors (AR) in cold stress (1 or 7 days in cold) in animals lacking main cardioinhibitive receptors—M<sub>2</sub> muscarinic receptors (M<sub>2</sub>KO). There was no change in receptor number in the right ventricles. In the left ventricles, there was decrease in binding to all cardiostimulative receptors (beta1-, and beta2-AR) and increase in cardiodepressive receptors (beta3-AR) in unstressed KO in comparison to WT. The cold stress in WT animals resulted in decrease in binding to beta1- and beta2-AR (to 37%/35% after 1 day in cold and to 27%/28% after 7 days in cold) while beta3-AR were increased (to 216% of control) when 7 days cold was applied. MR were reduced to 46% and 58%, respectively. Gene expression of M<sub>2</sub> MR in WT was not changed due to stress, while M<sub>3</sub> was changed. The reaction of beta1- and beta2-AR (binding) to cold was similar in KO and WT animals, and beta3-AR in stressed KO animals did not change. Adenylyl cyclase activity was affected by beta3-agonist CL316243 in cold stressed WT animals but CL316243 had almost no effects on adenylyl cyclase

activity in stressed KO. Nitric oxide activity (NOS) was not affected by BRL37344 (beta3-agonist) both in WT and KO animals. Similarly, the stress had no effects on NOS activity in WT animals and in KO animals. We conclude that the function of M<sub>2</sub> MR is substituted by beta3-AR and that these effects are mediated via adenylyl cyclase rather than NOS.

**Keywords** Cold stress · Muscarinic receptors · Beta-adrenoceptors · Heart · Adenylyl cyclase · Nitric oxide synthase

## Introduction

Three  $\beta$ -adrenoceptor subtypes have been characterized to these days but only two of them have been previously assumed to exist in the heart (Lands et al. 1967):  $\beta_1$ -AR and  $\beta_2$ -AR. Both these subtypes produce positive inotropic and chronotropic effects. All  $\beta$ -adrenoceptors ( $\beta$ -AR) are members of the G-protein-coupled receptor family (GPCR).  $\beta_1$ -AR couples to G<sub>s</sub> proteins, stimulates adenylyl cyclase (AC), which subsequently leads to increase in cAMP intracellular levels. The sufficiency of cAMP is the key point in activation of protein kinase A (PKA), which phosphorylates also the L-type Ca<sup>2+</sup> channels and thus promotes calcium influx and enhances contraction. The G-protein coupling, signaling pathways, and functional effects specific for the  $\beta_2$ -AR resembles  $\beta_1$  subtype. Accumulated evidence indicates that at least in the rat and murine heart, stimulation of  $\beta_1$ -AR causes not only positive inotropic and chronotropic effects, but can also promote apoptosis of cardiomyocytes (Xiao et al. 1999). Persistent  $\beta_1$ -AR stimulation changes the receptor signaling pathway from PKA to Ca<sup>2+</sup>/calmodulin-dependent protein kinase II

**Electronic supplementary material** The online version of this article (doi:10.1007/s10571-011-9781-3) contains supplementary material, which is available to authorized users.

J. Benes · M. Novakova · V. Farar · V. Riljak ·  
J. Myslivecek (✉)  
Institute of Physiology, 1st Faculty of Medicine, Charles  
University, Albertov 5, 128 00 Prague, Czech Republic  
e-mail: jmys@lf1.cuni.cz

J. Rotkova · V. Farar · V. Riljak · J. Myslivecek  
Laboratory of Physiology, Institute of Health Sciences,  
Technical University, Liberec, Czech Republic

R. Kvetnansky  
Institute of Experimental Endocrinology, Slovak Academy  
of Sciences, Bratislava, Slovakia

(CaMKII) predominance, leading to myocyte maladaptive remodeling (Xiao et al. 2006). On the other hand, prolonged  $\beta_2$ -AR activation switches the receptor G-protein coupling from  $G_s$  to  $G_i$  and thereby possesses antiapoptotic effect resulting in cardioprotection (Communal et al. 1999; Chesley et al. 2000; Xiao et al. 2006). Challenge about the existence of another heart  $\beta$ -AR came at the end of the last century, when the 3rd  $\beta$ -adrenergic subtype,  $\beta_3$ -AR, was identified in the heart. The presence of  $\beta_3$ -AR mRNA has been confirmed repeatedly in the heart (Gauthier et al. 2000; Myslivecek et al. 2006) and the  $\beta_3$ -AR protein has been also identified using immunohistochemical detection (De Matteis et al. 2002). Furthermore, the presence of  $\beta_3$ -AR in human atrial tissue using a selective monoclonal antibody was demonstrated (Chamberlain et al. 1999). In full contrast with the other  $\beta$ -AR subtypes, stimulation of the  $\beta_3$ -AR produced a marked decrease in cardiac contractility in human heart (Gauthier et al. 2000). The negative inotropic effects were noted in many cases, when  $\beta_3$ -adrenoceptor agonists were used (Gauthier et al. 1998, 1999; Tavernier et al. 2003). Compared to  $\beta_1$ - and  $\beta_2$ -AR, the  $\beta_3$ -AR presents a relative in vitro and in vivo lack of desensitization following activation with agonists (Nantel et al. 1993). These features suggest that expression of the  $\beta_3$ -AR in the heart may have pathophysiological significance. In the heart,  $\beta_3$ -AR are not coupled to  $G_s$ , like  $\beta_1$ - and  $\beta_2$ -AR, but to the  $G_i$  protein. In human ventricles activation of  $G_i$  proteins causes an activation of the nitric oxide (NO) pathway, probably implicating the endothelial NO synthase (eNOS), which is expressed both in endothelial cells and cardiomyocytes (Gauthier et al. 1998; Xiao et al. 1999; Schulz et al. 2005; Moens et al. 2010). The NO production induces an activation of guanylyl cyclase leading to an increase in intracellular cyclic guanosine monophosphate (cGMP). Alternatively, NO could regulate cardiac function in a cGMP-independent way through modification of other proteins as cytochrome *c* oxidase or L-type calcium channel. It is supposed that  $\beta_3$ -AR/NO pathway could act as a negative feedback mechanism opposing the positive inotropic influences of catecholamines in the heart. When  $\beta_3$  agonist was applied, changes in the heart activity or gene expression of  $\beta_3$ -AR in the heart were shown repeatedly (Gauthier et al. 1998, 1999, 2000; Moniotte et al. 2001; Tavernier et al. 2003), although no direct evidence of  $\beta_3$ -AR binding sites in the heart exist. Moreover, role of the  $\beta_3$ -AR in physiological and pathophysiological conditions has not been evaluated yet.

The opposing effects on the heart rate and on the force of heart muscle contraction are mediated via muscarinic receptors and the mammal heart tissue is realized as  $M_2$  predominant organ. Muscarinic receptors (MR), similarly to  $\beta$ -adrenoceptors, belong to G protein-coupled receptor family. To date, five muscarinic receptor subtypes have

been described and cloned (Wess et al. 2003). The odd-numbered subtypes ( $M_1$ ,  $M_3$ ,  $M_5$ ) stimulate phospholipase C (PLC; via pertussis toxin-insensitive Gq protein), which cleaves phosphatidylinositolbisphosphate ( $PIP_2$ ) to inositoltrisphosphate ( $IP_3$ ) and diacylglycerol (DAG). The even-numbered subtypes ( $M_2$ ,  $M_4$ ) inhibit adenylyl cyclase (AC; via pertussis toxin-sensitive  $G_i$  protein), i.e., they decrease the amount of cyclic adenosine monophosphate (Moscona-Amir et al. 1988) and decrease the activity of protein kinase A (PKA). In the last decade, all muscarinic receptor subtypes became available (Wess et al. 2003, 2007) from which  $M_2$  muscarinic receptor knockout (Gomez et al. 2001) is of special interest in research of heart regulation as  $M_2$  muscarinic receptors are predominant muscarinic receptor subtype in the heart (regulating heart rate, contractility, atrio-ventricular conduction). In atria of these mice there was no change in heart rate after carbachol while in wild type bradycardia was induced (Gomez et al. 1999).

Also, the heart function can be also affected by another receptor type—i.e.,  $\alpha_1$ -adrenoceptors (Brodde et al. 2006). These receptors have cardiostimulative functions. However, the maximum positive inotropic effect following  $\alpha_1$ -AR stimulation is by far less than that evoked by  $\beta$ -AR stimulation in the human heart (Brodde et al. 2006).

We have recently shown that heart stress reaction comprise also muscarinic receptors (Myslivecek et al. 2004, 2008). Therefore, exposure of  $M_2$  MR KO mice to stress could reveal the role of both  $M_2$  muscarinic receptors and also of cardioinhibitive  $\beta_3$ -adrenoceptors in the heart reaction to stress.

Moreover, we have repeatedly shown that activation of one heart (or lung) receptor system (i.e., muscarinic or adrenergic) affects not only activated system but also antagonistic system ((Myslivecek et al. 1996, 2004, 2007).

Therefore, we tested two hypotheses:

1. The number of cardiostimulative adrenoceptors would be decreased as a result of trend to maintain heart homeostasis in unstressed  $M_2$ KO mice.
2. The inhibition of cardiac adenylyl cyclase system would be provided by  $\beta_3$ -adrenoceptors in  $M_2$ KO mice. Moreover, the coping with stress would be also taken over by  $\beta_3$ -adrenoceptors when  $M_2$  muscarinic receptors lack.

## Methods

### Experimental Animals

The  $M_2$  muscarinic receptor mice lacking  $M_2$  muscarinic receptor clone was generated in Wess laboratory (Gomez et al. 1999) and then bred in our animal facility (Prague,

Czech Republic). Animals were treated in accordance with the legislature of the Czech Republic and the EU legislature, and the experimental protocol was approved by the Committee for the Protection of Experimental Animals of the 1st Medical Faculty, Charles University, Prague. The wild type line was mixed 129J1/CF1 line. Control animals were maintained under controlled environmental conditions (12/12 light/dark cycle,  $22 \pm 1^\circ\text{C}$ , light on at 8 a.m.). Food and water were available ad libitum. Male  $M_2$ KO animals and their WT counterparts (weighting 20–25 g, 11–13 weeks old) were used in the study.

### Cold Stress

The animals (WT and KO) were exposed to cold for 1 day (24 h) or 7 days in conditions simulating natural situation. In the biological night (from 8 p.m. to 8 a.m.) the animals were exposed to the temperature  $5.91 \pm 0.38^\circ\text{C}$ , while in the biological day the temperature rise to  $9.73 \pm 0.59^\circ\text{C}$ . The light/dark cycle was the same as in the control animal. The temperature in the experimental space was checked every 10 min using thermometric chip (Maxim Integrated Products, Inc., Sunnyvale, CA, USA). Animals were housed three per cage. At the end of experiment, animals were sacrificed by decapitation; hearts were collected, connective tissue was carefully discarded, the left and right ventricles were isolated, flash frozen and kept in  $-80^\circ\text{C}$  until the experiments were performed.

### Gene Expression of Muscarinic Receptor Subtypes ( $M_1$ – $M_5$ ) Using Real-Time PCR TaqMan Assays

Total mRNA was isolated using chloroform-isopropanol (RNA Bee, TelTest, TX, USA) method according to manufacturer's instructions. RNA yield and integrity was evaluated spectrophotometrically (Tecan M200 Nanoquant, detection of 2  $\mu\text{l}$  of sample in 16 wells at the moment) at  $A1 = 260\text{ nm}$  and  $A1/A2 = 260/280\text{ nm}$ , respectively. Samples with  $A1/A2$  between 1.6 and 1.9 were used for downstream procedures. Total RNA was purified to eliminate potentially contaminating genomic DNA using recombinant DNase (Ambion). Purified mRNA was subsequently transcribed into cDNA using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare). qPCR was performed using TaqMan probes (Applied Biosystems, probe numbers:  $M_1$ : Mm01231010\_m1,  $M_2$ : Mm01167087\_m1,  $M_3$ : Mm01338409\_m1,  $M_4$ : Mm01331561\_s1,  $M_5$ : Mm01701883\_s1) with Roche qPCR Mastermix (Roche) using following protocol: 2 min at  $50^\circ\text{C}$ , 10 min at  $95^\circ\text{C}$  followed by 50 cycles 15 s at  $95^\circ\text{C}$  and 1 min at  $60^\circ\text{C}$  in a final volume 10  $\mu\text{l}$ . In order to determine the relative gene expression, the Delta-Delta-Ct (ddCt) method was used. The levels of analyzed transcripts were normalized to the level of the reference gene

transcript (18SrRNA, which level was practically the same in WT and KO). Then, for each sample the following formula was used: normalized ratio =  $2^{CT1-CT2}$ , where CT1 is CT of reference transcript and CT2 is CT of target transcript, where CT is the cycle threshold. After the qPCR reaction, melting curve analysis was performed to confirm the specificity of the analyzed transcript. No-template controls (NTC) and non-reverse transcription reactions (NRT) were performed as negative controls.

### Receptor Binding

We performed receptor binding on membranes prepared as follows: the tissue was weighted and homogenized in ice cold Tris-EDTA buffer (Tris-HCl 50 mmol/l, EDTA 2 mmol/l, pH adjusted to 7.4) for determination of total  $\beta$ -adrenergic receptors and muscarinic receptors (Myslivecek et al. 2007) or in another buffer (Tris-HCl 50 mmol/l,  $\text{MgCl}_2$  100 mmol/l, GTP 300  $\mu\text{mol/l}$ , Tiron 1  $\mu\text{mol/l}$ , ascorbic acid 1 mmol/l) for determination of  $\beta_3$ -adrenoceptors (Muzzin et al. 1994). The homogenate was centrifuged at  $600\times g$  for 10 min at  $4^\circ\text{C}$ , the supernatant was collected and the sediment was re-suspended in the buffer and centrifuged again using the same conditions. Supernatants were mixed and centrifuged for 25 min at  $32,000\times g$  at  $4^\circ\text{C}$ . The supernatant was discarded; the sediment was re-suspended in the buffer and centrifuged again in the same velocity and time (25 min,  $32,000\times g$ ,  $4^\circ\text{C}$ ). The experiments were performed similarly as has been reported before (Myslivecek et al. 2007). The amount of receptor binding sites was determined in duplicates using following conditions: (a) total  $\beta_1$ -adrenoceptor +  $\beta_2$ -adrenoceptor binding sites ( $B_{\text{max}}$ ): concentration rank 93.75–3000 pmol/l [ $^3\text{H}$ ]CGP 12177, non-specific binding was determined with 50  $\mu\text{mol/l}$  propranolol; (b)  $\beta_3$ -adrenoceptor binding sites: 4.68–150 nmol/l [ $^3\text{H}$ ]SB 206606, non-specific binding was determined with 1 mmol/l SR59230A; (c) muscarinic receptors binding sites: 65–2000 pmol/l [ $^3\text{H}$ ]QNB, non-specific binding was determined with 5  $\mu\text{mol/l}$  atropine. The incubation was performed at  $38^\circ\text{C}$  and lasted 60 min with [ $^3\text{H}$ ]CGP 12177, 30 min with [ $^3\text{H}$ ]SB 206606, and 120 min with [ $^3\text{H}$ ]QNB. All incubation times were adjusted previously (Muzzin et al. 1994; Myslivecek et al. 2007). The amount of binding sites ( $B_{\text{max}}$ ) per mg protein (determined using BCA a method kit; Sigma) and the affinity constant ( $K_D$ ) was computed by non-linear regression using GraphPad Prism 5.01 program (GraphPad Software). Affinity constants ( $K_D$ ) were used for the “single-point” measurement to determine the number of receptors saving the amount of tissue needed, using following saturating concentrations of radioligands (2000 pmol/l [ $^3\text{H}$ ]CGP 12177, 1500 pmol/l

[<sup>3</sup>H]QNB, and 120 nmol/l [<sup>3</sup>H]SB 206606 using the equation as previously.  $\beta_1$ - and  $\beta_2$ -adrenoceptors were determined using co-incubation of membranes with 400 pmol/l [<sup>3</sup>H]CGP, and with subtype-selective antagonists in triplicates ( $10^{-7}$  mol/l CGP 20712A,  $\beta_1$ -adrenoceptors or  $10^{-8}$  mol/l ICI 118.552,  $\beta_2$ -adrenoceptors).

### Adenylyl Cyclase Activity

We measured the basal level of cAMP and forskolin-stimulated activity of adenylyl cyclase using modified method of Hoffer et al. (2005) in left ventricles. Membranes were incubated in HBSS buffer (Hank's Stock Solutions, i.e., measurement of basal cAMP level) with or without presence of 40  $\mu$ mol/l forskolin (stimulated adenylyl cyclase activity) for 10 min at 37°C. The reaction was stopped by adding 0.2 N HCl. Then, the mixture was incubated for 20 min at RT, what was followed by centrifugation at  $10,000\times g$  for 10 min. Supernatants were saved for measurement of cAMP and pellets were used to measure protein content (BCA assay, Sigma). cAMP content was measured using an enzyme immunoassay kit (Cayman Chemical) at  $\lambda = 413$  nm on a plate reader (Sunrise, Tecan). The final amount of cAMP was expressed as pmol/mg protein.

### $\beta_3$ -adrenoceptor Effect on Adenylyl Cyclase Activity

For the investigation of  $\beta_3$ -adrenergic receptors ( $\beta_3$ -AR) mediated changes in adenylyl cyclase activity the tissue homogenates (murine left ventricles) were pre-incubated with preferential  $\beta_3$ -AR agonist CL 316243 (100 nM) 10 min at room temperature. Immediately the activity of adenylyl cyclase was determined using enzyme immunoassay kit as described above.

### Determination of Nitric Oxide Synthase Activity

The determination of nitric oxide synthase activity (NOS) in tissue homogenates (murine right ventricles) was performed by the Ultrasensitive Colorimetric NOS Assay Kit (Oxford Biomedical Research, Inc., USA). The first phase of the experiment (in microcentrifuge tube) was proceeded with tissue homogenates (30  $\mu$ l) mixed with 50 mM HEPES with 0.5 mM EDTA (200  $\mu$ l), NADPH Part A containing NADP<sup>+</sup>, Glucose 6-Phosphate and L-Arginine (10  $\mu$ l), and NADPH Part B containing Glucose 6-Phosphate dehydrogenase (10  $\mu$ l). After mixing and incubating for 1 h at 37°C (water bath) the reaction mixtures were chilled on ice for 5 min and subsequently nitrate reductase (10  $\mu$ l) was added to each sample. After vortexing and incubating for 20 min at room temperature the reaction

mixtures were centrifuged at 12,500 rpm for 5 min at 4°C. The amount of protein (determined using the Pierce BCA Protein Assay Kit) in the reaction mixtures (total volume of 0.26 ml) was within the range of 138–339  $\mu$ g. The second phase of the experiment (in flat-bottom microtiter plate) was performed with nitrite standard solutions (100  $\mu$ l) diluted from 100 to 0.5  $\mu$ M in duplicates and samples (100  $\mu$ l) also in duplicates followed by addition of the Griess reagents, SA in 3 N HCl (50  $\mu$ l), and NED (50  $\mu$ l). After shaking for 5 min at room temperature the absorbance was measured at 540 nm in multi-detection microplate reader (Synergy HT).

### $\beta_3$ -adrenoceptor Effect NOS Activity

For the investigation of  $\beta_3$ -adrenergic receptors ( $\beta_3$ -AR) mediated changes in NO-synthase (NOS) activity the tissue homogenates (murine left ventricles) were pre-incubated with preferential  $\beta_3$ -AR agonist BRL 37344 (1 mM) 10 min at room temperature. The time dependence (0, 5, 10, 15, 30 min) of NOS activation by BRL 37344 was determined in preliminary experiments showing 10 min as start of peak level of activation. Immediately the activity of NOS was determined using the Ultrasensitive Colorimetric NOS Assay Kit (Oxford Biomedical Research, Inc.).

### Statistical Analysis


Results are presented as mean  $\pm$  S.E.M. and each group represents an average of 6 animals. Statistical differences among groups were determined by one-way or two-way analysis of variance (ANOVA), and for multiple comparisons an adjusted *t*-test modified by SNK (Student–Newman–Keuls) correction was used. Values of  $P < 0.05$  were considered to be significant. When appropriate, Student's *t*-test was used.

## Results


### Basic Binding Characteristics

In unstressed animals, we have found changes in the amount of  $\beta_1$ -,  $\beta_2$ -, and  $\beta_3$ - adrenoceptors binding sites in the left ventricles (compare Figs. 1, 2) and no changes in right ventricles (data not shown).  $\beta_1$ -,  $\beta_2$ -AR were decreased (Fig. 1a, b vs. Fig. 2a, b to approximately one half, *t*-test,  $P = 0.0039$ , degrees of freedom,  $df = 10$ ) in comparison to WT as a result of M<sub>2</sub> muscarinic receptors knockout,  $\beta_3$ -AR were doubled (please compare Figs. 1c, 2c) in comparison to control (*t*-test,  $P = 0.001$ ,  $df = 10$ ). The affinity of receptors ( $K_D$ ) was not affected by M<sub>2</sub>

**Fig. 1** Changes of receptor binding during exposure to cold in wild type animals in left ventricles. *Abscissa*: number of days in cold. *Ordinate*: receptor binding expressed as  $B_{\max}$  [fmol/mg prot.]. **a, b, c, d**: appropriate type of receptor is marked in the heading



**Fig. 2** Changes of receptor binding during exposure to cold in knockout animals. *Abscissa*: number of days in cold. *Ordinate*: receptor binding expressed as  $B_{\max}$  [fmol/mg prot.]. **a, b, c, d**: appropriate type of receptor is marked in the heading



muscarinic receptor knockout ( $245.2 \pm 43.94$  pmol/l vs.  $207.8 \pm 19.25$  pmol/l for  $\beta_1/\beta_2$ -AR WT and KO, respectively;  $36.84 \pm 5.7$  pmol/l vs.  $38.1 \pm 10.5$  pmol/l for MR WT and KO, respectively) suggesting changes in receptor levels but not in their affinities to ligands without change in the receptor affinity. In addition to changes in  $\beta$ -adrenoceptors, we also found remaining binding to muscarinic receptors (see Figs. 1d, 2d,  $t$ -test,  $P = 0.0003$ ,  $df = 10$ ).

#### The Cold Stress Effects on Receptor Binding

The reaction to cold stress in WT animals was chamber specific. While there was important receptor reaction to cold in left ventricles, we did not find any change in receptor numbers in right ventricles. Similarly to WT animals, there was no change in receptor number in right ventricles of  $M_2$ KO mice.



**Table 1** Sequences of used primers and conditions of PCR

Gene	Primer sequence	Annealing temperature (°C)/time (s)	Number of cycles
TH	For: 5'-GAAGGGCCTCTATGCTACCCA-3' Rev: 5'-TGGGCGCTGGATACGAGA-3'	63/30	35
DBH	For: 5'-GACTCAACTACTGCCGGCACGT-3' Rev: 5'-CTGGGTGCACTTGTCTGTGCAGT-3'	60/30	35
PNMT	For: 5'-TACCTCCGCAACAACACTACGC-3' Rev: 5'-AAGGCTCCTGGTTCCTCTCG-3'	60/30	35
GAPDH	For: 5'-AGATCCACAACGGATACATT-3' Rev: 5'-TCCCTCAAGATTGTCAGCAA-3'	60/60	30

The cold stress in WT animals resulted in decrease in  $\beta_1$ - and  $\beta_2$ -AR (both after 1 day stay in the cold and after 7 days in cold) and also to dramatic decrease in MR in the heart left ventricles (see Fig. 1a, b). Exactly, there was decrease in  $\beta_1$ -AR to 37% of control in animals living in cold for 1 day and decrease to 27% of control after 7 days in cold (one-way ANOVA,  $P = 0.0007$ ,  $F = 20.94$ ,  $df = 10$ ).  $\beta_2$ -AR were diminished to 35% after 1 day and to 28% after 7 days in cold, respectively (one-way ANOVA,  $P = 0.0003$ ,  $F = 27.33$ ,  $df = 10$ ). On the other hand,  $\beta_3$ -AR (Fig. 1c) were increased (to 216% of control) when 7 days cold was applied (one-way ANOVA,  $P < 0.0001$ ,  $F = 31.80$ ,  $df = 17$ ). MR were reduced (Fig. 1d) to 46% and to 58%, respectively (one-way ANOVA,  $P = 0.0182$ ,  $F = 5.298$ ,  $df = 17$ ). The magnitude of changes expressed as percent of WT unstressed animals is shown in Tables 1, 2.

The reaction of cardiostimulative  $\beta_1$ - and  $\beta_2$ -adrenoceptors to cold was similar in KO animals to that in WT animals (see Fig. 2a, b). There was decrease in  $\beta_1$ -AR number after 1 day cold (to 45% of KO control) and after 7 days cold (to 32% of KO control). The changes in  $\beta_2$ -AR

were almost same as those in WT:  $\beta_2$ -AR decreased to 44% and to 29% in KO animals (while there was decrease to 35% and to 28% in WT), respectively (see Fig. 1b). In contrast to cardioinhibitive receptors in wild types,  $\beta_3$ -AR in KO animals did not change in reaction to cold (see Fig. 2c). The magnitude of changes expressed as percent of WT unstressed animals is shown in Table 2. As a result of  $M_2$  gene disruption, there was no change in MR number in the left ventricles (see Fig. 2d). The magnitude of changes expressed as percent of WT unstressed animals is shown in Table 2.

#### The Changes in Muscarinic Gene Expression in Unstressed and Stressed Animals

In order to better characterize the changes in muscarinic receptors we have investigated the changes in muscarinic receptor gene expression ( $M_1$ – $M_5$  subtypes) in WT and KO animals. As expected,  $M_2$  muscarinic receptors were not expressed in KO animals (therefore not depicted on Fig. 3). In addition to that, the gene expression of  $M_1$  and  $M_5$  muscarinic receptors was undetectable in the unstressed and stressed wild types as well as in unstressed and stressed knockouts.  $M_4$  muscarinic receptors were not changed (see Fig. 3d, e) in WT and KO by stress. On the other hand,  $M_3$  muscarinic receptors gene expression was changed (see Fig. 3b, c) in cold stress (one-way ANOVA,  $P = 0.0293$ ,  $F = 4.11$ ,  $df = 26$ ) in WT but not in KO animals. The magnitude of changes expressed as percent of WT unstressed animals is shown in Table 3.

#### Adenylyl Cyclase Activity Changes During Cold Stress


Adenylyl cyclase activity increased in unstressed WT animals when it was stimulated by forskolin which was abolished by CL 316243 (see Fig. 4a). CL 316243 alone had no effect on adenylyl cyclase activity in unstressed animals (Fig. 4a, one-way ANOVA,  $P = 0.0072$ ,  $F = 5.347$ ,  $df = 23$ ). In contrast, CL 316243 was able to increase adenylyl cyclase activity after one (Fig. 4c,

**Table 2** The proportional changes in binding sites in the left ventricles summarizing the magnitude of changes between groups

Genotype	Receptor subtype	Exposure to stress		
		Unstressed	1-day-stressed	7-day-stressed
WT	$\beta_1$ -AR	100 $\pm$ 15%	37 $\pm$ 6%*	27 $\pm$ 3%*
$M_2$ KO		53 $\pm$ 10%*	24 $\pm$ 5%*	17 $\pm$ 7%*
WT	$\beta_2$ -AR	100 $\pm$ 10%	35 $\pm$ 8%*	28 $\pm$ 4%*
$M_2$ KO		54 $\pm$ 10%	24 $\pm$ 5%*	16 $\pm$ 7%*
WT	$\beta_3$ -AR	100 $\pm$ 8%	82 $\pm$ 10%	219 $\pm$ 19%*
$M_2$ KO		208 $\pm$ 22%*	222 $\pm$ 38%	228 $\pm$ 30%
WT	MR	100 $\pm$ 15%	46 $\pm$ 5%*	58 $\pm$ 14%*
$M_2$ KO		13 $\pm$ 3%*	15 $\pm$ 4%	7 $\pm$ 2%

WT unstressed animals are considered as standard (100%), \* $P < 0.05$  significant difference from unstressed WT

**Fig. 3** Changes of gene expression of muscarinic receptor subtypes ( $M_1$ – $M_5$ ) during exposure to cold in wild type and knockout animals. *Abscissa*: number of days in cold. *Ordinate*: the relative amount of mRNA expressed in A.U. [arbitrary units]. **M2 WT**:  $M_2$  muscarinic receptor gene expression, KO animals are not shown as  $M_2$  MR were deleted.  $M_1$  and  $M_5$  MR were not detectable. **a**:  $M_2$  in WT, **b**:  $M_3$  in WT, **c**:  $M_3$  in KO, **d**:  $M_4$  in WT, **e**:  $M_4$  in KO



one-way ANOVA,  $P < 0.0001$ ,  $F = 13.37$ ,  $df = 23$ ) and 7 days cold (Fig. 4e, one-way ANOVA,  $P = 0.0087$ ,  $F = 5.63$ ,  $df = 18$ ). In stressed animals, forskolin also increased the amount of cAMP produced by adenylyl cyclase, but CL 316243 did not abolish these effects (Figs. 4c, e). In KO animals, forskolin was not able to increase the adenylyl cyclase activity in unstressed animals (Fig. 4b), there was only difference between combined treatment with CL 316243 with forskolin and other groups (one-way ANOVA,  $P = 0.0005$ ,  $F = 9.26$ ,  $df = 23$ ). When stress was applied (after 1 or 7 days) there was marked increase after forskolin treatment (Fig. 4d, 1 day: one-way ANOVA,  $P = 0.0183$ ,  $F = 4.05$ ,  $df = 27$ ; 7 days: (Fig. 4f) one-way ANOVA,  $P = 0.0019$ ,

$F = 6.91$ ,  $df = 25$ ). In contrast to WT animals, CL 316243 had almost no effects on adenylyl cyclase activity in KO animals itself (Fig. 4b, d, f); it only abolished the forskolin effects after 7 days cold.

#### Nitric Oxide Synthase Activity During Cold Stress

As it can be deduced from Fig. 5, BRL 37344 was not able to stimulate NOS activity both in WT animals (Fig. 5a (one-way ANOVA,  $P = 0.2352$ ,  $F = 1.451$ ,  $df = 35$ )) and KO animals (Fig. 5b (one-way ANOVA,  $P = 0.5565$ ,  $F = 0.8030$ ,  $df = 35$ ). Similarly, the stress had no effects on NOS activity in WT animals (after 1 or 7 days in cold) as well as on KO animals.

**Table 3** The proportional changes in gene expression of M1–M5 muscarinic receptor subtypes in the left ventricles summarizing the magnitude of changes between groups

Genotype	Receptor subtype	Exposure to stress		
		Unstressed	1-day-stressed	7-day-stressed
WT	M <sub>1</sub> MR	Non detectable		
M <sub>2</sub> KO				
WT	M <sub>2</sub> MR	100 ± 14%	142 ± 24%	70 ± 19%
M <sub>2</sub> KO		Non detectable		
WT	M <sub>3</sub> MR	100 ± 15%	52 ± 13%*	42 ± 7%*
M <sub>2</sub> KO		56 ± 11%*	70 ± 18%	44 ± 7%
WT	M <sub>4</sub> MR	100 ± 19%	111 ± 38%	129 ± 20%
M <sub>2</sub> KO		111 ± 27%	86 ± 14%	103 ± 19%
WT	M <sub>5</sub> MR	Non detectable		
M <sub>2</sub> KO				

WT unstressed animals are considered as standard (100%), \**P* < 0.05 significant difference from unstressed WT

#### Changes in Gene Expression of Catecholamine Synthesizing Enzymes

The changes of gene expression of catecholamine synthesizing enzymes are shown in supplementary material.

#### Discussion

Our results show that gene disruption of M<sub>2</sub> gene itself changed receptor levels on cardiac tissue membranes and that this effects was limited to the left ventricles. This is an important fact, as the trend for maintaining homeostasis between antagonistic receptors is not present in the right ventricles. That means only physiologically important heart regions are able to change the other (antagonistic) receptor properties. Concerning the mechanism, it is the most probable that the antagonistic receptor regulation is caused by heterologous regulation (i.e., local mechanism) as it is region specific. In other case, all regions should be affected. The fact that in case of one subtype receptor down-regulation there is also down-regulation of antagonistic receptor was demonstrated multiple times (Lee and Fraser 1993; Paraschos and Karliner 1994; Myslivecek et al. 1998).

Another finding of this article is that cold stress is able to decrease the number of  $\beta_1$ -,  $\beta_2$ -adrenoceptor, and muscarinic receptor binding sites and to increase the number of  $\beta_3$ -adrenoceptor in left murine ventricles. In mice, lacking main M<sub>2</sub> muscarinic receptors was the loss of main cardioinhibitive receptors compensated by increase in  $\beta_3$ -adrenoceptors. This finding, according to our knowledge, is new. Concerning the


mechanism, the decrease of  $\beta_1$ - and  $\beta_2$ -AR could be caused by the decrease of protein translation and/or decrease of their membrane surface presentation. The data on  $\beta_3$ -AR [based on our previous findings (Tillinger et al. 2008)] suggest increase in  $\beta_3$ -AR gene expression. Also, it is necessary to point out that the previous study was performed on rat and the present results are from mice. Usually, strain differences exist.

We demonstrate here that knocking out of M<sub>2</sub> muscarinic receptors changes also the gene expression changes in left ventricles during stress reaction which is, according to our knowledge, also new finding. There is decrease in M<sub>3</sub> muscarinic receptor gene expression in WT, while the gene expression is not changed KO animals during cold stress. On the other hand, M<sub>2</sub> muscarinic receptor mRNA is not changed in WT animals suggesting that changes in muscarinic receptor binding are consequence of changes in protein properties (decrease in protein translation and/or decrease of their membrane surface presentation and/or increase of their removal from the membrane and/or degradation) rather than changes in gene expression. M<sub>3</sub> muscarinic receptors are coupled to PLC (Wang et al. 2007) and could have cardiostimulative effects. Therefore, their changes can be understood as a part of compensatory mechanisms with mutual interplay between cardiostimulating and cardioinhibitive receptors. But, in M<sub>3</sub> knockout animals, the changes in heart rate in comparison to WT animals after muscarinic agonist treatment are not substantial (Fisher et al. 2004) which question the role of M<sub>3</sub> muscarinic receptors in regulation of heart rate. Another possibility is that changes in M<sub>3</sub> gene expression are related to the ability to induce delayed cardioprotection which have been shown recently (Zhao et al. 2010).

The activity of adenylyl cyclase is importantly affected by  $\beta_3$ -adrenoceptor agonist which suggest that adenylyl cyclase can be regulated during cold stress reaction by  $\beta_3$ -ARs. As it has been demonstrated earlier (Gauthier et al. 2000),  $\beta_3$ -adrenoceptor can activate G<sub>i</sub> proteins which causes an activation of the nitric oxide (NO) pathway, probably implicating the endothelial NO synthase (eNOS). Our results show that CL 316243 (10,000 times more selective to  $\beta_3$ -adrenoceptors than to  $\beta_1$ - and  $\beta_2$ -adrenoceptors) was able to abolish the forskolin effects in WT unstressed animals. In contrast to that, in cold stress CL 316243 increases the amount of produced cAMP which suggests that  $\beta_3$ -adrenoceptor can switch from G<sub>i</sub> coupling to G<sub>s</sub> coupling. This is the properties of  $\beta_3$ -adrenoceptors in the adipose tissue (Hamilton and Doods 2008). Another possibility is that it can reveal the secondary state of  $\beta_3$ -adrenoceptor as it have been demonstrated by (Baker 2005). In summary, the increase of cAMP production by the  $\beta_3$ -AR activation is unobvious and (see Fig. 4) can be seen in cold stressed WT animals only. With deep contrast,




**Fig. 4** Changes of adenylyl cyclase activity during exposure to cold in wild type and knockout animals. *Abcissa*: type of the drug added to the mixture (*bas* basal level, i.e., no drug was added, *fors* forskolin, *CL* CL 316243, *fors + CL* forskolin and CL 316243 was applied). *Ordinate*: the amount of measured cAMP expressed as pg/ml/mg prot. **a**: WT AC: unstressed WT animals, **b**: KO AC: unstressed KO animals, **c**: WT 1 day cold, **d**: KO 1 day cold, **e**: WT 7 days cold, **f**: KO 7 days cold: appropriate type of animals and stress



CL 316243 was not able to increase cAMP levels in KO animals (where  $\beta_3$ -AR (see Fig. 2) are constantly increased). This fact gives evidence about the compensatory role of  $\beta_3$ -AR in the heart when  $M_2$  MR are lacking. The possible interaction between increased level of cAMP and heart homeostasis should be evaluated further. As it has been demonstrated recently, there can be connection of  $\beta_3$ -AR to  $Ca^{++}$  signaling (Li et al. 2010) which could be also the possibility how to explain increase cAMP levels in WT only. In these experiments (Li et al. 2010),  $\beta_3$ -AR inhibits the  $Ca^{++}$  currents induced by activation of  $\beta_1$  and  $\beta_2$ -AR, which could explain the differences in CL 316243 effects in WT and KO animals (different numbers of  $\beta_3$ -AR binding sites).

It was demonstrated that modulation of NOS (rather eNOS) activity and increase in NO formation after the application of BRL 37344 is specifically coupled to a stimulation of the cardiac  $\beta$ -AR (Moens et al. 2010). We have investigated whether the preferential  $\beta_3$ -AR agonist BRL 37344 induces an activation of the NOS in the murine right ventricles. The activities of NOS expressed as  $\mu$ moles of NO produced/ $\mu$ g protein/unit time were compared at tissue homogenates non-stimulated and stimulated with BRL (1 mM). No NOS activation was observed after application of BRL 37344 in tested samples of tissue homogenates. These data make the possibility that NOS is activated by  $\beta_3$ -AR in cold stress rather improbable.



**Fig. 5** Changes of nitric oxide synthase activity during exposure to cold in wild type (**a**) and knockout (**b**) animals. *Abscissa*: type stimulation used for NOS determination (*basal* basal level, i.e., no drug was added, *stim* BRL 37344 treatment). Number of days in cold are shown as 1 or 7 cold (i.e., 1 day in the cold, 7 days in the cold). *Ordinate*: the amount of measured NO expressed as  $\mu\text{mol/l/mg prot/min}$

In conclusion, we demonstrate here that the cold stress decreases the number of  $\beta_1$ -,  $\beta_2$ -adrenoceptors and muscarinic receptors and increases the number of  $\beta_3$ -adrenoceptors in left murine ventricles (in WT animals). The stress is connected with increased levels of catecholamines that are able to decrease  $\beta_1$ -,  $\beta_2$ -adrenoceptors. These receptors are cardiostimulative (activate adenylyl cyclase, increase  $\text{Ca}^{++}$  release from sarcoplasmic reticulum (Krizanova et al. 2007) increasing the force and rate of heart contraction). Therefore, when  $\beta_1$ -,  $\beta_2$ -adrenoceptors are decreased, opposite receptors should change accordingly (i.e., there should be decrease in MR that inhibit adenylyl cyclase, decrease  $\text{Ca}^{++}$  release from reticulum and decrease the heart rate and contraction). In addition to that  $\text{M}_3$  muscarinic receptor gene expression decreases were observed during cold stress in WT but not in KO animals.

As no attitude in muscarinic receptor subtype detection is available, we can only speculate that minor ( $\text{M}_3$ ) muscarinic receptor subtype, which is considered as cardiostimulating, should changed in the same manner as other receptors to maintain the balance between antagonistic receptors.  $\beta_3$ -adrenoceptors were assumed to be cardioinhibitive. We demonstrate here, that increase in  $\beta_3$ -AR is connected with increase of adenylyl cyclase activity that is probably due to imbalance between  $\beta_1$ -AR ( $\beta_2$ -AR) and  $\beta_3$ -AR as deduced from the  $\beta_3$ -AR changes in KO animals (where  $\beta_3$ -AR did not increased the adenylyl cyclase activity). Please also note, that the basal adenylyl cyclase activity decreases when comparing control, 1 day and 7 days cold.  $\beta_3$ -AR are not coupled to NOS.

When  $\text{M}_2$  muscarinic receptors are lacking then there is persistent increase in  $\beta_3$ -adrenoceptors which leads to abolishing of  $\beta_3$ -AR induced adenylyl cyclase activity increase. Similarly as in WT,  $\beta_3$ -AR are not coupled to NOS in KO animals. This give evidence that  $\beta_3$ -AR substitute the role of lacking MR in the cold stressed animals in which they are not able to increase the adenylyl cyclase activity.

**Acknowledgments** This study was supported by grant GACR309/09/0406 and by Grant GAUK 111409. Technical assistance of Petra Svatosova is greatly acknowledged.

## References

- Baker JG (2005) Evidence for a secondary state of the human  $\beta_3$ -adrenoceptor. *Mol Pharmacol* 68:1645–1655
- Brodde OE, Bruck H, Leineweber K (2006) Cardiac adrenoceptors: physiological and pathophysiological relevance. *J Pharmacol Sci* 100:323–337
- Chamberlain PD, Jennings KH, Paul F, Cordell J, Berry A, Holmes SD, Park J, Chambers J, Sennitt MV, Stock MJ, Cawthorne MA, Young PW, Murphy GJ (1999) The tissue distribution of the human  $\beta_3$ -adrenoceptor studied using a monoclonal antibody: direct evidence of the  $\beta_3$ -adrenoceptor in human adipose tissue, atrium and skeletal muscle. *Int J Obes Relat Metab Disord* 23:1057–1065
- Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, Crow MT (2000) The  $\beta_2$ -adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. *Circ Res* 87:1172–1179
- Communal C, Singh K, Sawyer DB, Colucci WS (1999) Opposing effects of  $\beta_1$ - and  $\beta_2$ -adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. *Circulation* 100:2210–2212
- De Matteis R, Arch JR, Petroni ML, Ferrari D, Cinti S, Stock MJ (2002) Immunohistochemical identification of the  $\beta_3$ -adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. *Int J Obes Relat Metab Disord* 26:1442–1450
- Fisher JT, Vincent SG, Gomez J, Yamada M, Wess J (2004) Loss of vagally mediated bradycardia and bronchoconstriction in mice

- lacking M2 or M3 muscarinic acetylcholine receptors. *FASEB J* 18:711–713
- Gauthier CLV, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. *J Clin Invest* 198:1377–1384
- Gauthier C, Tavernier G, Trochu JN, Leblais V, Laurent K, Langin D, Escande D, Le Marec H (1999) Interspecies differences in the cardiac negative inotropic effects of beta(3)-adrenoceptor agonists. *J Pharmacol Exp Ther* 290:687–693
- Gauthier C, Langin D, Balligand J-L (2000) b3-adrenoceptors in the cardiovascular system. *Trends Pharmacol Sci* 21:426–431
- Gomez J, Shannon H, Kostenis E, Felder C, Zhang L, Brodtkin J, Grinberg A, Sheng H, Wess J (1999) Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. *Proc Natl Acad Sci USA* 96:1692–1697
- Gomez J, Zhang L, Kostenis E, Felder CC, Bymaster FP, Brodtkin J, Shannon H, Xia B, Duttaroy A, Deng CX, Wess J (2001) Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. *Life Sci* 68:2457–2466
- Hamilton BS, Doods HN (2008) Identification of potent agonists acting at an endogenous atypical [beta]3-adrenoceptor state that modulate lipolysis in rodent fat cells. *Eur J Pharmacol* 580:55–62
- Hoffert JD, Chou CL, Fenton RA, Knepper MA (2005) Calmodulin is required for vasopressin-stimulated increase in cyclic AMP production in inner medullary collecting duct. *J Biol Chem* 280:13624–13630
- Krizanova O, Mysliveček J, Tillinger A, Jurkovicova D, Kubovcova L (2007) Adrenergic and calcium modulation of the heart in stress: from molecular biology to function. *Stress (Amsterdam, Netherlands)* 10:173–184
- Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr (1967) Differentiation of receptor systems activated by sympathomimetic amines. *Nature* 214:597–598
- Lee NH, Fraser CM (1993) Cross-talk between m1 muscarinic acetylcholine and beta 2-adrenergic receptors. cAMP and the third intracellular loop of m1 muscarinic receptors confer heterologous regulation. *J Biol Chem* 268:7949–7957
- Li H, Liu Y, Huang H, Tang Y, Yang B, Huang C (2010) Activation of beta3-adrenergic receptor inhibits ventricular arrhythmia in heart failure through calcium handling. *Tohoku J Exp Med* 222:167–174
- Moens AL, Yang R, Watts VL, Barouch LA (2010) Beta 3-adrenoceptor regulation of nitric oxide in the cardiovascular system. *J Mol Cell Cardiol* 48:1088–1095
- Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL (2001) Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. *Circulation* 103:1649–1655
- Moscona-Amir E, Henis YI, Sokolovsky M (1988) Guanosine 5'-triphosphate binding protein (Gi) and two additional pertussis toxin substrates associated with muscarinic receptors in rat heart myocytes: characterization and age dependency. *Biochemistry* 27:4985–4991
- Muzzin P, Boss O, Mathis N, Revelli JP, Giacobino JP, Willcocks K, Badman GT, Cantello BC, Hindley RM, Cawthorne MA (1994) Characterization of a new, highly specific, beta 3-adrenergic receptor radioligand, [3H]SB 206606. *Mol Pharmacol* 46:357–363
- Mysliveček J, Trojan S, Tucek S (1996) Biphasic changes in the density of muscarinic and beta-adrenergic receptors in cardiac atria of rats treated with diisopropylfluorophosphate. *Life Sci* 58:2423–2430
- Mysliveček J, Lisa V, Trojan S, Tucek S (1998) Heterologous regulation of muscarinic and beta-adrenergic receptors in rat cardiomyocytes in culture. *Life Sci* 63:1169–1182
- Mysliveček J, Ricny J, Palkovits M, Kvetnansky R (2004) The effects of short-term immobilization stress on muscarinic receptors, beta-adrenoceptors, and adenylyl cyclase in different heart regions. *Ann N Y Acad Sci* 1018:315–322
- Mysliveček J, Novakova M, Palkovits M, Krizanova O, Kvetnansky R (2006) Distribution of mRNA and binding sites of adrenoceptors and muscarinic receptors in the rat heart. *Life Sci* 79:112–120
- Mysliveček J, Duysen EG, Lockridge O (2007) Adaptation to excess acetylcholine by downregulation of adrenoceptors and muscarinic receptors in lungs of acetylcholinesterase knockout mice. *Naunyn-Schmiedeberg's Arch Pharmacol* 376:83–92
- Mysliveček J, Tillinger A, Novakova M, Kvetnanský R (2008) Regulation of adrenoceptor and muscarinic receptor gene expression after single and repeated stress. *Ann N Y Acad Sci* 1148:367–376
- Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, Marullo S (1993) The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. *Mol Pharmacol* 43:548–555
- Paraschos A, Karliner JS (1994) Receptor crosstalk: effects of prolonged carbachol exposure on beta 1-adrenoceptors and adenylyl cyclase activity in neonatal rat ventricular myocytes. *Naunyn-Schmiedeberg's Arch Pharmacol* 350:267–276
- Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL (2005) Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. *Pharmacol Ther* 108:225–256
- Tavernier G, Tomaniantz G, Erfanian M, Heymann MF, Laurent K, Langin D, Gauthier C (2003) beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. *Cardiovasc Res* 59:288–296
- Tillinger A, Mysliveček J, Nováková M, Krizanova O, Kvetnanský R (2008) Gene Expression of Adrenoceptors in the Hearts of Cold-Acclimated Rats Exposed to a Novel Stressor. *Ann N Y Acad Sci* 1148:393–399
- Wang H, Lu Y, Wang Z (2007) Function of cardiac M3 receptors. *Auton Autacoid Pharmacol* 27:1–11
- Wess J, Duttaroy A, Zhang W, Gomez J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, Faraci FM, Deng C, Yamada M (2003) M1–M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. *Recept Channels* 9:279–290
- Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat Rev* 6:721–733
- Xiao RP, Cheng H, Zhou YY, Kuschel M, Lakatta EG (1999) Recent advances in cardiac beta(2)-adrenergic signal transduction. *Circ Res* 85:1092–1100
- Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, Han Q (2006) Subtype-specific alpha1- and beta- adrenoceptor signaling in the heart. *Trends Pharmacol Sci* 27:330–337
- Zhao J, Su Y, Zhang Y, Pan Z, Yang L, Chen X, Liu Y, Lu Y, Du Z, Yang B (2010) Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up-regulating cyclooxygenase-2 expression. *Br J Pharmacol* 159:1217–1225